Sign In

Login

Password

Forgot Password ? Sign Up

Imatinib (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Imatinib" in Serbian language version.

refsWebsite
Global rank Serbian rank
10doi.org
2nd place
4th place
9nih.gov
4th place
8th place
2archive.org
6th place
5th place
1harvard.edu
18th place
28th place

archive.org (Global: 6th place; Serbian: 5th place)

doi.org (Global: 2nd place; Serbian: 4th place)

  • Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. Deininger, M. W.; Druker, B. J. (септембар 2003). „Specific targeted therapy of chronic myelogenous leukemia with imatinib”. Pharmacological Reviews. 55 (3): 401—23. PMID 12869662. doi:10.1124/pr.55.3.4. . Epub 2003 Jul 17.
  • Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. Vigneri, P.; Wang, J. Y. (фебруар 2001). „Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase”. Nature Medicine. 7 (2): 228—34. PMID 11175855. doi:10.1038/84683. 
  • Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15; Droogendijk, H. J.; Kluin-Nelemans, H. J.; Van Doormaal, J. J.; Oranje, A. P.; Van De Loosdrecht, A. A.; Van Daele, P. L. (2006). „Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial”. Cancer. 107 (2): 345—51. PMID 16779792. doi:10.1002/cncr.21996. 
  • Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. Lassila, M.; Allen, T. J.; Cao, Z.; Thallas, V.; Jandeleit-Dahm, K. A.; Candido, R.; Cooper, M. E. (мај 2004). „Imatinib attenuates diabetes-associated atherosclerosis”. Arteriosclerosis, Thrombosis, and Vascular Biology. 24 (5): 935—42. PMID 14988091. doi:10.1161/01.ATV.0000124105.39900.db. . Epub 20 04 Feb 26.
  • Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med. Reeves, P. M.; Bommarius, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, A.; Chavan, R.; Feinberg, M. B.; Veach, D.; Bornmann, W.; Sherman, M.; Kalman, D. (јул 2005). „Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases”. Nature Medicine. 11 (7): 731—9. PMID 15980865. doi:10.1038/nm1265. . Epub 2005 Jun 26.
  • Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  • Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  • Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o. 
  • Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  • Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

harvard.edu (Global: 18th place; Serbian: 28th place)

adsabs.harvard.edu

  • Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o. 

nih.gov (Global: 4th place; Serbian: 8th place)

ncbi.nlm.nih.gov

  • Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. Deininger, M. W.; Druker, B. J. (септембар 2003). „Specific targeted therapy of chronic myelogenous leukemia with imatinib”. Pharmacological Reviews. 55 (3): 401—23. PMID 12869662. doi:10.1124/pr.55.3.4. . Epub 2003 Jul 17.
  • Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. Vigneri, P.; Wang, J. Y. (фебруар 2001). „Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase”. Nature Medicine. 7 (2): 228—34. PMID 11175855. doi:10.1038/84683. 
  • Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15; Droogendijk, H. J.; Kluin-Nelemans, H. J.; Van Doormaal, J. J.; Oranje, A. P.; Van De Loosdrecht, A. A.; Van Daele, P. L. (2006). „Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial”. Cancer. 107 (2): 345—51. PMID 16779792. doi:10.1002/cncr.21996. 
  • Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. Lassila, M.; Allen, T. J.; Cao, Z.; Thallas, V.; Jandeleit-Dahm, K. A.; Candido, R.; Cooper, M. E. (мај 2004). „Imatinib attenuates diabetes-associated atherosclerosis”. Arteriosclerosis, Thrombosis, and Vascular Biology. 24 (5): 935—42. PMID 14988091. doi:10.1161/01.ATV.0000124105.39900.db. . Epub 20 04 Feb 26.
  • Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med. Reeves, P. M.; Bommarius, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, A.; Chavan, R.; Feinberg, M. B.; Veach, D.; Bornmann, W.; Sherman, M.; Kalman, D. (јул 2005). „Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases”. Nature Medicine. 11 (7): 731—9. PMID 15980865. doi:10.1038/nm1265. . Epub 2005 Jun 26.
  • Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  • Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  • Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  • Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.